Diarrhea is more common and sometimes more severe with flutamide than with other NSAAs.  In a comparative trial of combined androgen blockade for prostate cancer, the rate of diarrhea was 26% for flutamide and 12% for bicalutamide.  Moreover, 6% of flutamide-treated patients discontinued the drug due to diarrhea, whereas only % of bicalutamide-treated patients did so.  In the case of antiandrogen monotherapy for prostate cancer, the rates of diarrhea are 5–20% for flutamide, 2–5% for bicalutamide, and 2–4% for nilutamide .  In contrast to diarrhea, the rates of nausea and vomiting are similar among the three drugs. 
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.